Related Experiment Video
Updated: Jul 7, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications]
1Centre Antoine-Lacassagne, Département d'oncologie médicale, Nice, France.
Abstract:
Approximately 90 % of gastrointestinal tumors (GISTs) harbor an activating mutation in KIT or PDGFR alpha oncogene known to confer imatinib sensitivity. Imatinib is a tyrosine kinase inhibitor of KIT and PDGFRs that yields a 6-months progression-free survival (PFS) rate of 80 % in patients with advanced GISTs. Several studies have shown that response to imatinib in GIST patients mainly depends on the mutational status of KIT or PDGFR alpha. Moreover, most if not all patients treated with imatinib for advanced GIST will secondarily develop progressive disease under treatment. In the majority of cases, such progressions are the result of acquired resistance due to occurrence of secondary C-KIT mutations; especially for GIST with primary exon 11 mutations. Sunitinib is another approved drug and an inhibitor of multiple tyrosine kinases including KIT, PDGFR alpha as well as PDGFR beta and VEGFRs which are associated with angiogenesis. Sunitinib, in phase II and III trials was associated with durable clinical benefit in nearly 25 % of patients with advanced GIST resistant/intolerant to imatinib. Clearly, a better knowledge of the molecular mechanisms underlying the resistance to imatinib as well as the development of a new class of broad-spectrum tyrosine kinase inhibitors may allow in the near future new individualized therapeutic strategies for GISTs patients.
Insights
Gastrointestinal stromal tumors (GISTs) often develop resistance to imatinib due to secondary KIT mutations. Understanding these resistance mechanisms is key to developing new targeted therapies for advanced GIST.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Activating mutations in KIT or PDGFR alpha oncogenes are present in ~90% of gastrointestinal stromal tumors (GISTs), conferring sensitivity to imatinib.
- Imatinib, a tyrosine kinase inhibitor, shows an 80% 6-month progression-free survival (PFS) rate in advanced GISTs, but acquired resistance frequently develops.
- Resistance to imatinib in GIST is often driven by secondary mutations in KIT, particularly in patients with primary exon 11 mutations.
Purpose of the Study:
- To review the molecular mechanisms of imatinib resistance in GIST.
- To discuss the role of secondary mutations in treatment failure.
- To highlight the potential for new therapeutic strategies, including broad-spectrum tyrosine kinase inhibitors.
Main Methods:
- Literature review of studies on GIST genetics, imatinib response, and resistance mechanisms.
- Analysis of clinical trial data for imatinib and sunitinib in advanced GIST.
- Exploration of molecular pathways involved in GIST tumorigenesis and drug resistance.
Main Results:
- Imatinib response is strongly correlated with the mutational status of KIT or PDGFR alpha.
- Acquired resistance to imatinib, often due to secondary KIT mutations, is a common cause of disease progression.
- Sunitinib, a multi-targeted tyrosine kinase inhibitor, has shown clinical benefit in approximately 25% of imatinib-resistant GIST patients.
Conclusions:
- A deeper understanding of imatinib resistance mechanisms is crucial for advancing GIST treatment.
- Development of novel, broad-spectrum tyrosine kinase inhibitors is needed.
- Future therapeutic strategies for GIST patients will likely involve individualized approaches based on molecular profiles.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD: